DE60219196T2 - BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN - Google Patents

BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN Download PDF

Info

Publication number
DE60219196T2
DE60219196T2 DE60219196T DE60219196T DE60219196T2 DE 60219196 T2 DE60219196 T2 DE 60219196T2 DE 60219196 T DE60219196 T DE 60219196T DE 60219196 T DE60219196 T DE 60219196T DE 60219196 T2 DE60219196 T2 DE 60219196T2
Authority
DE
Germany
Prior art keywords
alkyl
mmol
concentrated
product
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219196T
Other languages
German (de)
English (en)
Other versions
DE60219196D1 (de
Inventor
Bernard R. West Orange NEUSTADT
Hong Hackensack LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60219196D1 publication Critical patent/DE60219196D1/de
Publication of DE60219196T2 publication Critical patent/DE60219196T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60219196T 2001-11-30 2002-11-26 BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN Expired - Lifetime DE60219196T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
US334385P 2001-11-30
PCT/US2002/037915 WO2003048163A1 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (2)

Publication Number Publication Date
DE60219196D1 DE60219196D1 (de) 2007-05-10
DE60219196T2 true DE60219196T2 (de) 2008-01-03

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219196T Expired - Lifetime DE60219196T2 (de) 2001-11-30 2002-11-26 BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN

Country Status (18)

Country Link
US (2) US6875772B2 (OSRAM)
EP (1) EP1453836B1 (OSRAM)
JP (2) JP4429724B2 (OSRAM)
KR (1) KR20050044600A (OSRAM)
CN (1) CN1688581A (OSRAM)
AR (1) AR037681A1 (OSRAM)
AT (1) ATE358130T1 (OSRAM)
AU (1) AU2002352933A1 (OSRAM)
CA (1) CA2468658C (OSRAM)
DE (1) DE60219196T2 (OSRAM)
ES (1) ES2283625T3 (OSRAM)
HU (1) HUP0402324A3 (OSRAM)
IL (1) IL161573A0 (OSRAM)
MX (1) MXPA04005158A (OSRAM)
PE (1) PE20030653A1 (OSRAM)
TW (1) TW200300689A (OSRAM)
WO (1) WO2003048163A1 (OSRAM)
ZA (1) ZA200404168B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2002352933A1 (en) * 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists
NZ535169A (en) * 2002-03-12 2006-03-31 Wyeth Corp Process for making chiral 1,4-disubstituted piperazines
CA2500228A1 (en) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]-triazolo[1,5-c]pyrimidine derivative
NZ540493A (en) 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
EP1615930A2 (en) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
US20090124663A1 (en) * 2005-06-08 2009-05-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200803856A (en) 2005-09-02 2008-01-16 Mount Cook Biosciences Inc Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
EP3814355B1 (en) 2018-06-26 2025-12-24 Zhejiang Vimgreen Pharmaceuticals, Ltd Triazolotriazine derivatives as a2a receptor antagonists
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
US20230048888A1 (en) * 2019-12-26 2023-02-16 Zhejiang Vimgreen Pharmaceuticals, Ltd. Use of triazolotriazine derivative in treatment of diseases
JP7646873B2 (ja) * 2021-04-23 2025-03-17 チョン クン ダン ファーマシューティカル コーポレイション アデノシンＡ２ａ受容体アンタゴニストとしての化合物およびこれを含む薬学的組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) * 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
HUP0103921A3 (en) * 1998-09-22 2002-12-28 Kyowa Hakko Kogyo Kk [1,2,4]triazolo[1,5-c]pyrimidine derivatives and pharmaceutical compositions thereof
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
MXPA02011625A (es) 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
AR037243A1 (es) * 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
AU2002352933A1 (en) * 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
US7078408B2 (en) 2006-07-18
CA2468658A1 (en) 2003-06-12
AR037681A1 (es) 2004-12-01
EP1453836B1 (en) 2007-03-28
AU2002352933A1 (en) 2003-06-17
CA2468658C (en) 2009-04-14
HUP0402324A2 (hu) 2005-02-28
WO2003048163A1 (en) 2003-06-12
KR20050044600A (ko) 2005-05-12
US20050113380A1 (en) 2005-05-26
US20030191130A1 (en) 2003-10-09
IL161573A0 (en) 2004-09-27
PE20030653A1 (es) 2003-08-04
US6875772B2 (en) 2005-04-05
MXPA04005158A (es) 2004-08-11
ES2283625T3 (es) 2007-11-01
HK1064097A1 (en) 2005-01-21
ZA200404168B (en) 2005-09-02
ATE358130T1 (de) 2007-04-15
JP2010018634A (ja) 2010-01-28
TW200300689A (en) 2003-06-16
JP2005511697A (ja) 2005-04-28
DE60219196D1 (de) 2007-05-10
CN1688581A (zh) 2005-10-26
EP1453836A1 (en) 2004-09-08
HUP0402324A3 (en) 2008-09-29
JP4429724B2 (ja) 2010-03-10

Similar Documents

Publication Publication Date Title
DE60219196T2 (de) BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
DE60110219T2 (de) Adenosin a2a rezeptor antagonisten
DE60209251T2 (de) Adenosine a2a receptor antagonisten
JP4284182B2 (ja) アデノシンＡ２ａレセプターアンタゴニスト
DE60210944T2 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
DE60125335T2 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69409652T2 (de) Gefässverengende substituierte aryloxyalkyldiamine
AU2001268089A1 (en) Adenosine A2a receptor antagonists
EP1228059B1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE602004007658T2 (de) Indolderivate mit verbesserter antipsychotischer wirkung
DE69007905T2 (de) 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus.
DE69720715T2 (de) Hexahydro-pyrido (4,3-b)indolderivate als antipsychotische arzneimittel
DE3856501T2 (de) Schlafverbesserungsmittel
DE69632032T2 (de) Gefässverschliessende substituierte 2,3- dihydro -1,4- dioxinopyridine
DE69417560T2 (de) Gefässverengende subtituierte dihydropyranopyridine
HK1064097B (en) Bicyclic [1,2,4] -triazole adenosine a2a receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition